盐酸嘧啶二胺 | 63-56-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 盐酸嘧啶二胺
• 英文名称: thonzylamine hydrochloride
• 英文别名: N-(4-methoxy-benzyl)-N',N'-dimethyl-N-pyrimidin-2-yl-ethylenediamine; hydrochloride；N-(4-Methoxy-benzyl)-N',N'-dimethyl-N-pyrimidin-2-yl-aethylendiamin; Hydrochlorid；Thonzylaminhydrochlorid；hydron;N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyrimidin-2-ylethane-1,2-diamine;chloride
• CAS: 63-56-9
• 化学式: C₁₆H₂₂N₄O*ClH
• 分子量: 322.838
• InChiKey: HRYJPHOTGFERGT-UHFFFAOYSA-N

物化性质

• 熔点：
  173-176°
• 沸点：
  bp2.2 185-187°
• 密度：
  1.2562 (rough estimate)
• 物理描述：
  Thonzylamine hydrochloride is a white crystalline powder with a faint odor . pH: 5.1-5.7 (2 % aqueous solution). (NTP, 1992)
• 溶解度：
  Very soluble (NTP, 1992)
• 碰撞截面：
  167.3 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
• 稳定性/保质期：
  稳定存储，避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.48
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S36
• 危险类别码：
  R20/21/22

反应信息

• 作为反应物：
  描述：

  盐酸嘧啶二胺 、 吡拉明马来酸盐 、 盐酸氯环嗪 生成 盐酸氯苯达诺
  参考文献：
  名称：

  COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN

  摘要：

  所声称的发明涉及到组成物，可以是液体、固体、凝胶、乳霜或凝胶胶囊的形式，包括镇痛剂，并且涉及到使用这些组成物治疗患有各种疼痛的患者的方法。

  公开号：

  US20140094438A1

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。
• Process for production of vinyl chloride polymer
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：EP0172427A2

  公开（公告）日：1986-02-26

  This process is a process for production of a vinyl chloride polymer by suspension polymerization or emulsion polymerization of vinyl chloride monomer or a mixture of vinyl chloride monomer with a vinyl monomer copolymerizable with said vinyl chloride monomer in an aqueous medium, characterized in that the polymerization is carried out in a polymerizer, the inner wall surface and portions of the auxiliary equipment thereof which may come into contact with the monomer during polymerization being previously coated with a scaling preventive comprising at least one selected from dyes, pigments and aromatic or heterocyclic compounds having at least 5 conjugated π bonds, while controlling the chloride ion concentration in the reaction mixture to not higher than 100 ppm. According to said process, scaling onto the inner wall surface of a polymerizer, etc. during polymerization can be prevented effectively and surely.

  该工艺是通过氯乙烯单体或氯乙烯单体与可与所述氯乙烯单体共聚的乙烯基单体混合物在水介质中进行悬浮聚合或乳液聚合来生产氯乙烯聚合物的工艺，其特征在于聚合是在聚合器中进行的、内壁表面及其辅助设备中可能在聚合过程中与单体接触的部分事先涂上一层防垢剂，该防垢剂至少包括一种选自染料、颜料和至少有 5 个共轭 π 键的芳香族或杂环化合物的防垢剂，同时控制反应混合物中的氯离子浓度不高于 100 ppm。根据上述工艺，可有效、可靠地防止聚合过程中聚合器等内壁表面结垢。
• IBUPROFEN SOLUTIONS FOR CAPSULE-FILLING AND CAPSULE PREPARTIONS
  申请人：Kowa Company, Ltd.

  公开号：EP1321140A1

  公开（公告）日：2003-06-25

  A fill liquid composition for capsules is produced by mixing ibuprofen, polyethylene glycol, water and terpenoid selected from menthol, limonene, borneol, dl-camphor, peppermint oil and so forth, and optionally one or more agents selected from antipyretic analgesic, anti-histamine, antitussive, expectorant, sympathetic nerve stimulant, central stimulant, hypnotic sedative and antiphlogistic, and solubilizing agent, viscous agent, pH adjuster, coloring agent, and the like, in order to exhibit the effects that the prevention of bitterness of ibuprofen and the quick-activeness of ibuprofen are consistently achieved.

  将布洛芬、聚乙二醇、水和选自薄荷醇、柠檬烯、龙脑、樟脑、薄荷油等的萜类化合物，以及可选的一种或多种选自解热镇痛剂、抗组胺剂、止咳剂、祛痰剂、交感神经刺激剂、中枢兴奋剂、催眠镇静剂和解热镇痛剂的药剂，以及增溶剂、粘稠剂、pH 值调节剂、着色剂等混合，制成一种胶囊填充液体组合物、以及增溶剂、粘稠剂、pH 值调节剂、着色剂等，以表现出布洛芬的防苦味效果和布洛芬的速效性。